Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

interferon pathway machinery) or nontargeted mRNAs. As a result, the standard of care to demonstrate the specificity of an observed RNAi-induced phenotype (namely the suppression of the targeted ...

The mechanisms by which the RNAi pathway can trigger specific gene expression changes in plants include both transcriptional and post-transcriptional regulation. These processes rely on specific base ...

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of ...

Homocysteine is not recycled back to methionine, but is further metabolized in the transsulfuration pathway. Interestingly, our data suggest an alternative link between methionine and CTH independent ...

The presentation titled, "Targeting Obesity with RNAi-based Therapies," was included ... both seek to intervene in a known biological pathway with strong support from human genetics studies ...